| Literature DB >> 33342967 |
Hidemasa Nakaminami1, Yuu Okamura1, Satomi Tanaka1, Takeaki Wajima1, Nobuo Murayama2, Norihisa Noguchi1.
Abstract
Currently, antimicrobial-resistant staphylococci, particularly methicillin-resistant Staphylococcus pseudintermedius (MRSP), are frequently isolated from canine superficial pyoderma in Japan. However, little is known regarding the nasal prevalence of MRSP in pet dogs. Here, we determined the prevalence of antimicrobial-resistant staphylococci in nares and affected sites of pet dogs with superficial pyoderma. Of the 125 nares and 108 affected sites of pet dogs with superficial pyoderma, 107 (13 species) and 110 (eight species) staphylococci strains, respectively, were isolated. The isolation rate of S. pseudintermedius from pyoderma sites (82/110 strains, 74.5%) was significantly higher than that from nares (57/107 strains, 53.3%) (P<0.01). Notably, the prevalence of MRSP (18/57 strains, 31.6%) in nares was equivalent to that in pyoderma sites (28/82 strains, 34.1%). Furthermore, the phenotypes and genotypes of antimicrobial resistance in MRSP strains from nares were similar to those from pyoderma sites. Our findings revealed that the prevalence of antimicrobial-resistant staphylococci in the nares of pet dogs with superficial pyoderma is the same level as that in affected sites. Therefore, considerable attention should be paid to the antimicrobial resistance of commensal staphylococci in companion animals.Entities:
Keywords: Staphylococcus aureus; Staphylococcus pseudintermedius; Staphylococcus schleiferi; antimicrobial resistance; pet dog
Mesh:
Substances:
Year: 2020 PMID: 33342967 PMCID: PMC7972875 DOI: 10.1292/jvms.20-0439
Source DB: PubMed Journal: J Vet Med Sci ISSN: 0916-7250 Impact factor: 1.267
Isolation rates of Staphylococcus species isolated from nares and pyoderma sites in pet dogs
| Species | No. (%) of isolates | ||
|---|---|---|---|
| Nares | Pyoderma | Total | |
| 5 (4.7) | 1 (0.9) | 6 (2.8) | |
| 2 (1.9) | 0 | 2 (0.9) | |
| 2 (1.9) | 0 | 2 (0.9) | |
| 1 (0.9) | 0 | 1 (0.5) | |
| 2 (1.9) | 0 | 2 (0.9) | |
| 0 | 3 (2.7) | 3 (1.4) | |
| 2 (1.9) | 3 (2.7) | 5 (2.3) | |
| 3 (2.8) | 0 | 3 (1.4) | |
| 57 (53.3) | 82 (74.5)* | 139 (64.1) | |
| 1 (0.9) | 1 (0.9) | 2 (0.9) | |
| 26 (24.3) | 18 (16.4) | 44 (20.3) | |
| 1 (0.9) | 1 (0.9) | 2 (0.9) | |
| 3 (2.8) | 0 | 3 (1.4) | |
| 0 | 1 (0.9) | 1 (0.5) | |
| 1 (0.9) | 0 | 1 (0.5) | |
| Not determineda | 1 (0.9) | 0 | 1 (0.5) |
Zero to two bacteria were detected in each subject. a, Species of the isolates could not be determined. *P<0.01, vs. nares.
Proportion of methicillin-resistant Staphylococcus pseudintermedius, methicillin-resistant Staphylococcus shleiferi, and methicillin-resistant Staphylococcus aureus isolated from nares and pyoderma sites in pet dogs
| Species | Origin (n) | No. (%) of isolates | |
|---|---|---|---|
| Nares (57) | 18 (31.6) | 39 (68.4) | |
| Pyoderma (82) | 28 (34.1) | 54 (65.9) | |
| Nares (26) | 8 (30.8) | 18 (69.2) | |
| Pyoderma (18) | 5 (27.8) | 13 (72.2) | |
| Nares (5) | 2 (40.0) | 3 (60.0) | |
| Pyoderma (1) | 0 | 1 (100.0) | |
Comparison of the antimicrobial susceptibility of Staphylococcus pseudintermedius strains isolated from nares and pyoderma sites in pet dogs
| Antimicrobial agent | Methicillin-resistant | Methicillin-susceptible | ||||||
|---|---|---|---|---|---|---|---|---|
| Nares (n=18) | Pyoderma (n=28) | Nares (n=39) | Pyoderma (n=54) | |||||
| MIC50 / MIC90 | R (%) | MIC50 / MIC90 | R (%) | MIC50 / MIC90 | R (%) | MIC50 / MIC90 | R (%) | |
| Ampicillin | 0.25 / 4 | - | 0.5 / 4 | - | ≤0.06 / 0.25 | - | ≤0.06 / ≤0.06 | - |
| Oxacillin | 0.5 / ≥256 | 88.9 | 1 /≥256 | 82.1 | 0.13 / 0.5 | 12.8 | ≤0.06 / ≤0.06 | 1.9 |
| Cephalexin | 4 / 128 | - | 1 / 16 | - | 2 / 64 | - | 0.25 / 0.5 | - |
| Imipenem | ≤0.06 / ≤0.06 | - | ≤0.06 / ≤0.06 | - | ≤0.06 / ≤0.06 | - | ≤0.06 / ≤0.06 | - |
| Fosfomycin | ≤0.5 / ≥256 | - | ≤0.5 / 64 | - | ≤0.5 / 128 | - | ≤0.5 / ≤0.5 | - |
| Enrofloxacin | 16 / 32 | - | 16 / 32 | - | 0.5 / 16 | - | ≤0.06 / 16 | - |
| Levofloxacin | 8 / 8 | 94.4 | 8 / 16 | 89.3 | 0.25 / 8 | 35.9 | ≤0.06 / 8 | 24.1 |
| Erythromycin | ≥256 / ≥256 | 94.4 | ≥256 / ≥256 | 89.3 | 0.13 / ≥256 | 30.8 | ≤0.06 / ≥256 | 40.7 |
| Lincomycin | ≥256 / ≥256 | - | ≥256 / ≥256 | - | 0.5 / ≥256 | - | 0.5 / ≥256 | - |
| Gentamicin | 8 / 32 | 50.0 | 8 / 16 | 46.4 | 0.5 / 16 | 17.9 | ≤0.13 / 8 | 7.4 |
| Minocycline | 1 / 4 | 0.0 | 2 / 8 | 0.0 | ≤0.5 / 1 | 0.0 | ≤0.5 / 8 | 0.0 |
| Chloramphenicol | 4 / 64 | 38.9 | 64 / 64 | 60.7 | 2 / 32 | 10.3 | 4 / 64 | 14.8 |
| Vancomycin | 0.5 / 0.5 | 0.0 | 0.5 / 1 | 0.0 | 0.5 / 1 | 0.0 | 0.5 / 1 | 0.0 |
MIC50 / MIC90, the minimum inhibitory concentrations (MICs) (µg/ml) that inhibit the growth of 50% / 90% of the strains. R, rate of resistant strains. The resistance breakpoints of the following antimicrobial agents were defined according to criteria from the CLSI [6]: oxacillin, ≥0.5 µg/ml; levofloxacin, ≥4 µg/ml; erythromycin, ≥8 µg/ml; gentamicin, ≥16 µg/ml; minocycline, ≥16 µg/ml; chloramphenicol, ≥32 µg/ml; vancomycin, ≥16 µg/ml. -, breakpoints were not defined.
Comparison of the antimicrobial susceptibility of Staphylococcus schleiferi strains isolated from nares and pyoderma sites in pet dogs
| Antimicrobial agent | Methicillin-resistant | Methicillin-susceptible | ||||||
|---|---|---|---|---|---|---|---|---|
| Nares (n=8) | Pyoderma (n=5) | Nares (n=18) | Pyoderma (n=13) | |||||
| MIC50 / MIC90 | R (%) | MIC50 / MIC90 | R (%) | MIC50 / MIC90 | R (%) | MIC50 / MIC90 | R (%) | |
| Ampicillin | 0.13 / 0.25 | - | 1 / 8 | - | ≤0.06 / 0.5 | - | ≤0.06 / 0.25 | - |
| Oxacillin | 2 / 4 | 87.5 | 0.5 / 128 | 60.0 | ≤0.06 / 8 | 11.1 | ≤0.06 / ≤0.06 | 7.7 |
| Cephalexin | 8 / 16 | - | 4 / 64 | - | 2 / 2 | - | 0.25 / 0.5 | - |
| Imipenem | ≤0.06 / ≤0.06 | - | ≤0.06 / ≤0.06 | - | ≤0.06 / ≤0.06 | - | ≤0.06 / ≤0.06 | - |
| Fosfomycin | 1 / 8 | - | ≤0.5 /≥256 | - | ≤0.5 / 16 | - | ≤0.5 / ≤0.5 | - |
| Enrofloxacin | 0.5 / 2 | - | 0.13 / 1 | - | 0.5 / 16 | - | 0.25 / 8 | - |
| Levofloxacin | 0.25 / 2 | 0.0 | 0.25 / 1 | 0.0 | 0.25 / 8 | 38.9 | 0.13 / 8 | 23.1 |
| Erythromycin | ≤0.06 / 0.13 | 0.0 | ≤0.06 / ≤0.06 | 0.0 | ≤0.06 / 16 | 11.1 | ≤0.06 / ≤0.06 | 0.0 |
| Lincomycin | 0.13 / 0.25 | - | 0.25 / 32 | - | 0.25 /≥256 | - | 0.13 / 0.5 | - |
| Gentamicin | 0.5 / 8 | 0.0 | ≤0.13 / 32 | 20.0 | 0.5 / 1 | 5.6 | ≤0.13 / 0.5 | 0.0 |
| Minocycline | ≤0.5 / ≤0.5 | 0.0 | ≤0.5 / ≤0.5 | 0.0 | ≤0.5 / ≤0.5 | 0.0 | ≤0.5 / ≤0.5 | 0.0 |
| Chloramphenicol | 2 / 2 | 0.0 | 2 / 4 | 0.0 | 2 / 2 | 0.0 | 4 / 4 | 7.7 |
| Vancomycin | 0.5 / 1 | 0.0 | 1 / 1 | 0.0 | 0.5 / 1 | 0.0 | 0.5 / 1 | 0.0 |
MIC50 / MIC90, the minimum inhibitory concentrations (MICs) (µg/ml) that inhibit the growth of 50% / 90% of the strains. R, rate of resistant strains. The resistance breakpoints of the following antimicrobial agents were defined according to criteria from the CLSI [6]: oxacillin, ≥0.5 µg/ml; levofloxacin, ≥4 µg/ml; erythromycin, ≥8 µg/ml; gentamicin, ≥16 µg/ml; minocycline, ≥16 µg/ml; chloramphenicol, ≥32 µg/ml; vancomycin, ≥16 µg/ml. -, breakpoints were not defined.
Comparison of the possession rates of antimicrobial resistance genes in Staphylococcus pseudintermedius strains isolated from nares and pyoderma sites in pet dogs
| Gene | No. (%) of strains | |||
|---|---|---|---|---|
| Methicillin-resistant | Methicillin-susceptible | |||
| Nares (n=18) | Pyoderma (n=28) | Nares (n=39) | Pyoderma (n=54) | |
| 17 (94.4) | 25 (89.3) | 12 (30.8) | 17 (31.5) | |
| 12 (66.6) | 17 (60.7) | 13 (33.3) | 24 (44.4) | |
| 4 (22.2) | 2 (7.1) | 3 (7.7) | 1 (1.9) | |
| 16 (88.9) | 25 (89.3) | 11 (28.2) | 23 (42.6) | |
| 0 | 1 (3.6) | 0 | 0 | |
Comparison of the possession rates of antimicrobial resistance genes in Staphylococcus shleiferi strains isolated from nares and pyoderma sites in pet dogs
| Gene | No. (%) of strains | |||
|---|---|---|---|---|
| Methicillin-resistant | Methicillin-susceptible | |||
| Nares (n=8) | Pyoderma (n=5) | Nares (n=18) | Pyoderma (n=13) | |
| 2 (25.0) | 1 (20.0) | 0 | 0 | |
| 0 | 0 | 1 (5.6) | 0 | |
| 0 | 1 (20.0) | 1 (5.6) | 0 | |
Molecular epidemiological features of Staphylococcus aureus strains isolated from nares and pyoderma sites in pet dogs
| Strain | Origin | Sequence type | Antimicrobial resistance gene | MSCRAMMs | Virulence factor | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NVM123 | Nares | 30 | - | + | - | - | - | + | - | + | - | + | + | + | + | + | - | - | + | + | + | - | - | - | + | + | - |
| NVM146a | Nares | 15 | - | - | - | - | - | - | + | + | + | + | + | + | + | - | - | - | - | - | - | + | + | + | + | - | + |
| NVM151a | Nares | 5 | + | + | - | - | + | - | + | + | + | + | + | + | + | - | + | + | + | + | - | + | + | - | + | - | + |
| NVM178 | Nares | 188 | - | - | - | - | - | + | + | + | + | + | + | + | + | - | - | - | - | - | - | + | + | - | + | - | + |
| NVM183a | Nares | 5 | + | + | - | + | + | - | + | + | + | + | + | + | + | - | + | + | + | + | + | + | + | - | + | - | + |
| MV103 | Pyoderma | 8 | - | - | + | + | - | - | + | + | + | + | + | + | + | - | - | - | - | - | - | + | - | - | + | - | + |
MSCRAMMs, Microbial Surface Components Recognizing Adhesive Matrix Molecules.